All News

Leadership shakeups at the CDC, legal challenges, and growing scrutiny of the childhood immunization schedule have disrupted US vaccine policy.

Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, affordability of classic therapies, and advancing AI in dermatology.

This year's most-watched video evaluated how President Donald Trump's rescission of several Biden-era executive orders may impact Medicaid and Medicare initiatives.

A recent review suggests women with ovarian or colorectal cancer face a higher risk of developing the other, highlighting the need for surveillance.

Check out the most popular stories and developments that happened in mental health care this year.

In-home step training for multiple sclerosis showed no improvement in ankle proprioception or muscle performance, highlighting challenges in exercise adherence.

Explore the latest breakthroughs in allergy treatments, including FDA approvals and emerging therapies that enhance patient care and address systemic challenges.

Baricitinib shows promising results for severe alopecia areata, with more than half of patients experiencing significant hair regrowth within a year.

Real-world evidence highlights the effectiveness of lisocabtagene maraleucel in treating relapsed or refractory chronic lymphocytic leukemia (R/R CLL).

Patients with generalized myasthenia gravis face significant barriers to diagnosis, creating the need for improved patient–health care interactions.

From oncology to cardiology, Institute for Value-Based Medicine® conversations highlighted the ways value-based care is reshaping access, equity, and outcomes.

Early phototherapy significantly enhances hair regrowth in alopecia areata, especially when started within a year of symptom onset.

Chronic kidney disease complicates cancer treatment, leading to reduced chemotherapy use. Personalized approaches are essential for optimal patient outcomes.

Readers of PHEO this year found value in research, conference coverage, and insights that touched on health outcomes and care quality.

Obstructive sleep apnea may increase Parkinson disease risk, but early CPAP treatment could significantly reduce this risk.

Angela Liu, PhD, MPH, speaks about her study that examined mental health care use by Medicare beneficiaries before and after switching from MA to TM.

Our conference coverage featured updates on clinical trials testing new treatments for NSCLC, bladder cancer, and breast cancer.

Heart failure deaths increasingly occur at home or in hospice, but racial, sex, and regional disparities persist in end-of-life care.

Explore how patient experience data shapes regulatory drug decisions, enhancing the patient-focused drug development initiative for better treatment outcomes.

The FDA approves Wegovy, the first oral GLP-1 pill, offering a new weight loss solution for those struggling with obesity and overweight.

The FDA approved subcutaneous mosunetuzumab for relapsed follicular lymphoma, providing a more convenient outpatient option.

ASCO 2025 highlighted breakthroughs, including improved cancer survival in key trials, new AI guideline tools, and expanding GLP-1 cancer research.

The benefit of trabectedin plus olaparib to all-comers with soft tissue sarcoma was marginal, but the response was more pronounced in certain subgroups.

The cardiac myosin inhibitor is expected to be available in the US in the second half of January 2026.

A look back at the breakthroughs in pulmonary fibrosis research, including FDA-approved treatments and innovative diagnostic techniques.

Studies indicate that ultrasound-based AI models significantly outperform sonographers in diagnosing ovarian cancer.

Fuzuloparib extended progression-free survival, regardless of the addition of apatinib in patients with newly diagnosed advanced ovarian cancer.

This year's top inflammation article highlighted the first FDA-approved treatment for patients with bronchiectasis.